论文部分内容阅读
目的 为观察经皮穿刺支气管动脉灌注CD3 AK治疗中晚期肺癌的近期疗效。方法 采用住院及门诊中晚期肺癌 3 2例为观察组 ,经皮支气管动脉灌注CD3 AK及化疗药物 ,每次灌注CD3 AK1× 10 9/5 0ml、吡柔比星 40mg、卡铂3 0 0mg、西艾克 4mg或威猛 (VM 2 6) 15 0mg。每 3～ 4周灌注 1次 ,2次为 1疗程。对照组为中晚期肺癌 2 0例 ,单纯采用支气管动脉化疗药物灌注 ,化疗药物与观察组相同 ,介入疗程也相同。结果 观察组CR 5例 ,PR 2 2例 ,有效率 (CR +PR)为 84.3 % ( 2 7/3 2 ) ,对照组CR 2例 ,PR 6例 ,有效率 (CR +PR)为 40 .0 % ( 8/2 0 ) ,实验组CD4 、CD4 /CD8比值均明显上升。两组毒副反应均较轻微。结论 CD3 AK对中晚期肺癌介入治疗有肯定的疗效 ,可能成为继LAK/IL 2之后有效和安全可靠的过继免疫疗法
Objective To observe the short-term efficacy of percutaneous transbronchial arterial infusion of CD3 AK in the treatment of advanced lung cancer. Methods Thirty-two hospitalized and outpatients with advanced lung cancer were used as the observation group. Percutaneous bronchial arterial infusion of CD3 AK and chemotherapeutic drugs were performed. Each infusion of CD3 AK1×10 9/5 ml, pirarubicin 40 mg, carboplatin 300 mg, West Ike 4mg or WM (VM 2 6) 15 0mg. Every 3 to 4 weeks perfusion, 2 times for a course of treatment. In the control group, 20 patients with advanced lung cancer were treated with bronchial arterial chemotherapy alone. The chemotherapy drugs were the same as those in the observation group, and the course of intervention was also the same. Results In the observation group CR 5 cases, PR 2 2 cases, the effective rate (CR +PR) was 84.3% (2 7/3 2), the control group CR 2 cases, PR 6 cases, the effective rate (CR +PR) was 40. 0 % ( 8/2 0 ), the ratio of CD4 and CD4/CD8 in the experimental group increased significantly. Both groups of toxic and side effects were mild. Conclusion CD3 AK has a positive effect on interventional treatment of advanced lung cancer and may be an effective and safe follow-up immunotherapy after LAK/IL 2